Fairvalue-Calculator Fairvalue-Calculator
EN DE

Protara Therapeutics, Inc (TARA) Fair Value & Analysis

Healthcare · US · Market cap $231M

Price$4.03
Fair Value$2.61
Upside-35.2%
Quality95/100
Evidence: Low Range $1.72 – $3.26

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Protara Therapeutics, Inc (TARA) currently trades at $4.03, while our model-based Fair Value estimate is $2.61 — implying the stock looks roughly 35.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Protara Therapeutics, Inc (TARA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $2.61 versus a price of $4.03 — about −35% (overvalued). Model-based estimate, not financial advice.
What is the fair value of TARA?
Our 21-model fair value for Protara Therapeutics, Inc is $2.61 (as of Jun 25, 2026), built from audited fundamentals. The current price is $4.03.
What is the quality score of TARA?
Protara Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.